First Real-World look at new kidney disease pill
NCT ID NCT07331259
Summary
This study will observe 83 adults with a rare kidney disease called C3 glomerulopathy (C3G) who are already taking the approved drug iptacopan. Researchers will review patients' medical records from before and after starting the medication to understand who gets treated and how they respond. The goal is to gather real-world information on patient characteristics and treatment outcomes to help doctors better manage this condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.